Clinical trials and other research with community representation organised by UK-CAB

Ongoing studies

The following studies include formal involvement of UK-CAB members as community representatives.

Research In Viral Eradication of HIV Reservoirs trial (RIVER study) – part of CHERUB group Damian Kelly
Low dose efavirenz study Paul Clift, Michael Harkin
POPPY study Memory Sachikonye
Beyond Undetectable: measuring what matters to people with HIV Alice Welbourne, Mark Platt
BHIVA working group on recording late HIV diagnoses Chenai Chimtashu
UK Collaborative HIV Cohort Study (UK-CHIC) Roy Trevelion
UK HIV drug resistance database  Simon Collins
PENTA (paediatric network) Polly Clayden
Oxford University vaccine study  Simon Collins
START community advisory board and the scientific steering committee (INSIGHT Research Network)  Simon Collins
D:A:D study (via HAART Oversight Committee)  Simon Collins
PROUD PrEP study Matthew Wiliams
MRC CTU Patient and Engagement: Ben Cromarty
ART-CC cohort Matthew Williams
HAUS study Memory Sachikonye
PRIME study (Positive tRansItions through the MEnopause) Fiona Pettit, Jane Shepherd, Janine McGregor
Clinical audit – HIV & STI feasibity study Esther Dixon-Williams
Fanconi study Ben Cromarty, Paul Clift
HIV respiratory study Memory Sachikonye
PhD Advisory Group – linkage to care

Completed studies

These studies with UK-CAB community represetnative have now been completed. For full information follow the link to the ISRCTN register entry.

PIVOT: Protease Inhibitor monotherapy Versus Ongoing Triple-therapy in the long-term management of HIV infection

ISRCTN register entry: ISRCTN04857074

This trial looked at whether a strategy of switching to boosted protease inhibitor (PI) monotherapy is non-inferior to continuing triple drug therapy for people who have achieved sustained virological suppression on combination therapy, in terms of the proportion of patients who maintain all their available drug treatment options after at least 3 years of follow-up, and to compare clinical events, safety, toxicity and health economic parameters between the two strategies.

Parallel group, open-label, multi-centre, randomised controlled trial.

Funder: NIHR Health Technology Assessment Programme
Sponsor: Medical Research Council
Contact: Dr Nick Paton, MRC Clinical Trials Unit
Community representation: Ben Cromarty (UK-CAB) – Trial Steering Committe and Robert James (UK-CAB) – Data Safety Monitoring Board.

HCQ-01: Hydroxychloroquine study

ISRCTN register entry: ISRCTN30019040

This study aimed to determine whether hydroxychloroquine decreases immune activation in HIV, measured by least a 25% reduction in CD8 T-cell activation after 48 weeks of treatment. The study also intends to examine the effects of hydroxychloroquine on viral load and CD4 T-cell count at week 48, and to assess safety of hydroxychloroquine in this patient population.

A phase II, multi-centre, randomised, double-blind, placebo-controlled clinical trial.

Funder: The Wellcome Trust
Sponsor: Medical Research Council Clinical Trials Unit
Contact: Dr Nick Paton, MRC Clinical Trials Unit
Community representation: Toju Cline-Cole (UK-CAB) – Trial Steering Committee

Published: January 29, 2016
Last edited: January 29, 2016